RAS Dialogue Blog
Join the discussion! Post comments, ask questions, and share information with RAS experts. Subscribe to receive notifications when a new RAS Dialogue article is posted.
-
KRAS somatic cancer-driver mutations in endometriosis without cancer: towards a molecular classification for endometriosis?
Drs. Yong, Orr, and Anglesio discuss how they found KRAS mutations—usually seen in cancer—in endometriosis tissue.
-
Oncogene turned bystander - How molecular context shapes KRas oncogenicity
Olesja Popow and Kevin Haigis share their insight into the persistent question of why KRAS mutations drive cancers in some tissues and not in others.
-
RAS Chat: An Interview with Kevan Shokat and Ziyang Zhang
Drs. Kevan Shokat and Ziyang Zhang discuss their work targeting the KRAS G12R and G12S mutations, and give their thoughts on the history and future of RAS research.
-
Consensus on the RAS Dimerization Hypothesis
Consensus on the RAS Dimerization Hypothesis
-
KRASG12C inhibition drives anti-tumour immunity in lung cancer but combinations with anti-PD1 immunotherapy may only benefit patients with ‘inflamed’ tumours
Using a novel immunogenic mouse model of KRAS-mutant lung cancer, the Downward lab asks the questions ‘what is the effect of KRAS G12C on the tumour microenvironment and on anti-tumour immunity?’ and ‘how well will anti-PD1 immunotherapy work in combination with KRAS G12C inhibitors?’